€11m · Other round · Healthtech · Seville, Spain
Seville-based Vaxdyn has raised €11m in a Series A led by Biovance Capital, with participation from the European Innovation Council Fund and Arcano Partners' Impacto Andalucía Innovación y Desarrollo vehicle. Biovance invested €4m and the Arcano-managed fund €3.6m. The financing will fund the first-in-human Phase 1 trial of K-VAX, Vaxdyn's lead vaccine candidate for antibiotic-resistant bacterial infections.
K-VAX is designed to prevent infections caused by Klebsiella pneumoniae and Acinetobacter baumannii, two Gram-negative bacteria associated with severe pneumonia, bloodstream infections and other hard-to-treat conditions. Vaxdyn says its platform targets outer-membrane proteins that cannot change substantially without losing their function, an approach intended to produce protection across multiple bacterial variants. That breadth remains to be demonstrated clinically.
The round finances the first human evidence
Moving from preclinical studies into Phase 1 changes the company's risk profile. The first trial will test safety and tolerability in humans before later studies can evaluate whether K-VAX generates useful protection. The €11m round therefore buys a defined evidence milestone rather than commercial scale: Vaxdyn must translate a platform-level biological claim into reproducible clinical data for a specific candidate.
The preventive mechanism also shapes the commercial proposition. A vaccine that reduces high-risk infections could lower reliance on antibiotics before resistance becomes a treatment problem, but the path to adoption is long. Vaxdyn will need clinical evidence across relevant strains and patient groups, a workable manufacturing process and partners capable of funding later-stage development.
The investor mix combines specialist biotech capital with European and Andalusian public instruments. Vaxdyn also has prior non-dilutive backing from the EIC Accelerator and CARB-X, which is separate from this €11m round. Together, those sources support the expensive transition into the clinic while keeping the new financing distinct from earlier programme funding.
